The Control of Tumour Oxygenation in Mice: The Importance of Tumour Site
Several bioreductive drugs have been shown to achieve impressive hypoxic/oxic toxicity ratios in vitro 1, 2. Their impact when given alone as anti tumour agents in vivo has been much less impressive, as might be predicted for drugs whose effects are predominantly on the hypoxic cell fraction. It was recognised that some means of increasing the proportion of hypoxic cells in tumours would have to be used if a substantial cell kill was to be achieved. Published reports of this strategy have mainly focused on the modification of tumour blood flow as the means of increasing hypoxia. Several classes of compound are capable of reducing blood flow in rodent tumours3, 4, but most studies involving the bioreductive cytotoxins have used either hydralazine or 5-HT5, 6, 7. A major problem with this combination is that a collapse in blood flow prevents the access of further cytotoxin. Two other, distinctly different methods have been used to achieve an increased hypoxia in mouse tumours, neither of which prevents the access of the drug.
KeywordsToxicity Oncol Sarcoma Melphalan Flavone
Unable to display preview. Download preview PDF.
- 3.D. G. Hirst and P. J. Wood, The control of tumour blood flow for therapeutic benefit, in “BIR Report 19, The Scientific Basis of Modern Radiotherapy”, N. J. McNally, ed., pp 76–80 (1989).Google Scholar
- 6.J. M. Brown, Exploitation of bioreductive agents with vasoactive drugs, in “Radiation Research, Proceedings of the 8th International Congress of Radiation Research”, E. M. Fielden, J. F. Fowler, J. H. Hendry, and D. Scott, eds, pp 719–724 (1987).Google Scholar
- 7.I. S. Stratford, J. Godden, N. Howells, P. Embling, and G. E. Adams, Manipulation of tumour oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumours, in “Radiation Research, Proceedings of the 8th International Congress of Radiation Research”, E. M. Fielden, J. F. Fowler, J. H. Hendry, and D. Scott, eds, pp 719–724 (1987).Google Scholar
- 10.S. Cole and L. Robbins, Manipulation of oxygenation in tumour xenografts with BW 12C and hydralazine: effect on response to radiation and to bioreductive cytotoxicity of raisonidazole or RSU 1069, Radiother.Oncol, (in press).Google Scholar
- 11.D. J. Chaplin, Hypoxia targeted chemotherapy: a role for vasoactive drugs, in “Radiation Research, Proceedings of the 8th International Congress of Radiation Research”, E. M. Fielden, J. F. Fowler, J. H. Hendry, and D. Scott, eds, pp 731–736 (1987).Google Scholar
- 13.S. A. Hill, K. B. Williams, and J. Denekamp, Vascular collapse after flavone acetic acid: a possible mechanism of its antitumour action, Eur.J.Cancer CI in.Oncol. 24 (in press).Google Scholar